BEETLER, Danielle J, Katelyn A BRUNO, Damian N DI FLORIO, Erika J DOUGLASS, Swikriti SHRESTHA, Carsten TSCHOEPE, Madeleine W CUNNINGHAM, Jan KREJČÍ, Julie DOBROVOLNÁ, Sabine PANKUWEIT, Dennis M MCNAMARA, Eun-Seok JEON, van Linthout SOPHIE, Lori A BLAUWET, Leslie T Jr COOPER a DeLisa FAIRWEATHER. Sex and age differences in sST2 in cardiovascular disease. Frontiers in Cardiovascular Medicine. Lausanne: Frontiers Media SA, 2023, roč. 9, January 2023, s. 1-19. ISSN 2297-055X. Dostupné z: https://dx.doi.org/10.3389/fcvm.2022.1073814.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Sex and age differences in sST2 in cardiovascular disease
Autoři BEETLER, Danielle J, Katelyn A BRUNO, Damian N DI FLORIO, Erika J DOUGLASS, Swikriti SHRESTHA, Carsten TSCHOEPE, Madeleine W CUNNINGHAM, Jan KREJČÍ (203 Česká republika, domácí), Julie DOBROVOLNÁ (203 Česká republika, domácí), Sabine PANKUWEIT, Dennis M MCNAMARA, Eun-Seok JEON, van Linthout SOPHIE, Lori A BLAUWET, Leslie T Jr COOPER a DeLisa FAIRWEATHER.
Vydání Frontiers in Cardiovascular Medicine, Lausanne, Frontiers Media SA, 2023, 2297-055X.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30201 Cardiac and Cardiovascular systems
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 3.600 v roce 2022
Kód RIV RIV/00216224:14110/23:00134703
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.3389/fcvm.2022.1073814
UT WoS 000923390600001
Klíčová slova anglicky biomarkers; heart failure; myocardial infarct; coronary artery disease; cardiomyopathy; congestive heart failure
Štítky 14110115, 14110518
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 2. 2. 2024 08:48.
Anotace
AimsThe goal of this study was to determine whether sex and age differences exist for soluble ST2 (sST2) for several cardiovascular diseases (CVDs). MethodsWe examined sST2 levels using an ELISA kit for myocarditis (n = 303), cardiomyopathy (n = 293), coronary artery disease (CAD) (n = 239), myocardial infarct (MI) (n = 159), and congestive heart failure (CHF) (n = 286) and compared them to controls that did not have CVDs (n = 234). ResultsMyocarditis occurred in this study in relatively young patients around age 40 while the other CVDs occurred more often in older individuals around age 60. We observed a sex difference in sST2 by age only in myocarditis patients (men aged 38, women 46, p = 0.0002), but not for other CVDs. Sera sST2 levels were significantly elevated compared to age-matched controls for all CVDs: myocarditis (p <= 0.0001), cardiomyopathy (p = 0.0009), CAD (p = 0.03), MI (p = 0.034), and CHF (p < 0.0001) driven by elevated sST2 levels in females for all CVDs except myocarditis, which was elevated in both females (p = 0.002) and males (p <= 0.0001). Sex differences in sST2 levels were found for myocarditis and cardiomyopathy but no other CVDs and were higher in males (myocarditis p = 0.0035; cardiomyopathy p = 0.0047). sST2 levels were higher in women with myocarditis over 50 years of age compared to men (p = 0.0004) or women under 50 years of age (p = 0.015). In cardiomyopathy and MI patients, men over 50 had significantly higher levels of sST2 than women (p = 0.012 and p = 0.043, respectively) but sex and age differences were not detected in other CVDs. However, women with cardiomyopathy that experienced early menopause had higher sST2 levels than those who underwent menopause at a natural age range (p = 0.02). ConclusionWe found that sex and age differences in sera sST2 exist for myocarditis, cardiomyopathy, and MI, but were not observed in other CVDs including CAD and CHF. These initial findings in patients with self-reported CVDs indicate that more research is needed into sex and age differences in sST2 levels in individual CVDs.
Návaznosti
NU22-02-00418, projekt VaVNázev: Klinické a proteomické biomarkery predikující reverzní remodelaci levé komory u pacientů s nově zjištěnou dilatační kardiomyopatií
Investor: Ministerstvo zdravotnictví ČR, Klinické a proteomické biomarkery predikujcí reverzní remodelování levé komory u pacientů s nově zjištěnou dilatační kardiomyopatií, Podprogram 1 - standardní
VytisknoutZobrazeno: 13. 7. 2024 20:32